By API User
Island reports highly positive pharmacokinetic data and reconfirms strong safety / tolerability data for ISLA-101 from its 24-subject Single Ascending Dose clinical study Data analysis shows required levels of ISLA-101 concentration in the blood were observed after only a single dose, achieving the study’s purpose This important new data is being used to prepare for … Continued
By API User
A Charles Darwin University (CDU) researcher is a step closer to replacing the needle to deliver drugs in the treatment of many chronic diseases. CDU pharmaceutical scientist Dr Nazim Nassar and RMIT biophysicist Professor Stefan Kasapis have filed an application in the US patent office for a new technology of a “gel-like casing” in an … Continued
By API User
Seaport Therapeutics, a clinical-stage biopharmaceutical company based around a unique drug delivery platform originally developed by Monash University researchers, has announced the closing of a US$100 million oversubscribed Series A financing round. The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health. Using … Continued
By API User
Celebrating 25-years and $31 million of impact and innovation in dementia research Dementia Australia Research Foundation is marking 25 years of supporting Australia’s best emerging researchers to explore, innovate and advance the field of dementia research with the release of its More than a Cure: 25 Years of Impact report. The report highlights some of … Continued
By API User
The strategic partnership will place UNSW students at local hospitals and streamline research collaboration opportunities. UNSW Sydney has signed an historic three-year Memorandum of Understanding (MoU) with the Mid North Coast Local Health District (MNCLHD), to help identify potential collaborative research opportunities and place undergraduate students in local rural health facilities. UNSW Vice-Chancellor … Continued
By API User
Highlights CLEO has appointed U.S.-based Lindus Health to manage U.S. clinical trials for its revolutionary ovarian cancer blood test Lindus Health is a leader in clinical trial management for the med-tech sector, with a strong record of timely and successful trial execution CLEO’s U.S. study will prospectively recruit up to 500 patients commencing next … Continued
By API User
Clairvoyant on target for potential commercialization of psilocybin treatment in 2025 VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company developing psilocybin treatment for alcohol use disorder (AUD), today announced that it is on target to potentially become the first in the world to commercialize clinically … Continued
By API User
NASA has announced that when humans take their first steps back on the moon after 50 years during the Artemis III mission, astronauts will cultivate and return lunar-grown plants to Earth for the first time. Known as Lunar Effects on Agricultural Flora (LEAF), the project will collect plant growth and development data that will help … Continued
By API User
Highlights CLEO’s second peer-reviewed dataset has now been published in medical journal “Diagnostics” The study concluded that CLEO’s test: Correctly identified most cancer cases that were missed by the standard marker CA125; Eliminated the majority of “false positive” results caused by CA125 use; and Correctly identified the majority of patients with early-stage ovarian cancers. Peer … Continued
By API User
New Location Positions CIL for Product Development and Future Growth TEWKSBURY, MA / ACCESSWIRE / March 15, 2024 / Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (13C), has announced it will be relocating and expanding its corporate headquarters to newly purchased space in Tewksbury, MA, … Continued
